498 related articles for article (PubMed ID: 25861829)
21. Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia.
Martín-Izquierdo M; Abáigar M; Hernández-Sánchez JM; Tamborero D; López-Cadenas F; Ramos F; Lumbreras E; Madinaveitia-Ochoa A; Megido M; Labrador J; Sánchez-Real J; Olivier C; Dávila J; Aguilar C; Rodríguez JN; Martín-Nuñez G; Santos-Mínguez S; Miguel-García C; Benito R; Díez-Campelo M; Hernández-Rivas JM
Haematologica; 2021 Aug; 106(8):2215-2223. PubMed ID: 32675227
[TBL] [Abstract][Full Text] [Related]
22. Survival benefits with transplantation in secondary AML evolving from myelodysplastic syndrome with hypomethylating treatment failure.
Shin SH; Yahng SA; Yoon JH; Lee SE; Cho BS; Eom KS; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim YJ
Bone Marrow Transplant; 2013 May; 48(5):678-83. PubMed ID: 23128572
[TBL] [Abstract][Full Text] [Related]
23. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
24. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
25. Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia.
Liao R; Xu Y; Chen M; Chen X; Zhan X; Sun J
Hematology; 2013 Jul; 18(4):191-7. PubMed ID: 23321417
[TBL] [Abstract][Full Text] [Related]
26. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation.
De Witte T; Van Biezen A; Hermans J; Labopin M; Runde V; Or R; Meloni G; Mauri SB; Carella A; Apperley J; Gratwohl A; Laporte JP
Blood; 1997 Nov; 90(10):3853-7. PubMed ID: 9354651
[TBL] [Abstract][Full Text] [Related]
27. Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation.
Del Cañizo Mf; Amigo Mf; Hernández JM; Sanz G; Núñez R; Carreras E; Alegre A; Cuesta B; Mataix R
Haematologica; 2000 Apr; 85(4):403-9. PubMed ID: 10756367
[TBL] [Abstract][Full Text] [Related]
28. Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study.
Myers KC; Furutani E; Weller E; Siegele B; Galvin A; Arsenault V; Alter BP; Boulad F; Bueso-Ramos C; Burroughs L; Castillo P; Connelly J; Davies SM; DiNardo CD; Hanif I; Ho RH; Karras N; Manalang M; McReynolds LJ; Nakano TA; Nalepa G; Norkin M; Oberley MJ; Orgel E; Pastore YD; Rosenthal J; Walkovich K; Larson J; Malsch M; Elghetany MT; Fleming MD; Shimamura A
Lancet Haematol; 2020 Mar; 7(3):e238-e246. PubMed ID: 31879230
[TBL] [Abstract][Full Text] [Related]
29. Pretreatment CD34
Jentzsch M; Geus U; Grimm J; Vucinic V; Pönisch W; Franke GN; Behre G; Niederwieser D; Schwind S
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1560-1566. PubMed ID: 30928626
[TBL] [Abstract][Full Text] [Related]
30. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience.
Aguilera DG; Vaklavas C; Tsimberidou AM; Wen S; Medeiros LJ; Corey SJ
J Pediatr Hematol Oncol; 2009 Nov; 31(11):803-11. PubMed ID: 19801947
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS): how can we improve outcomes in the near future?
Phillips GL
Leuk Res; 2012 Dec; 36(12):1490-5. PubMed ID: 22954609
[TBL] [Abstract][Full Text] [Related]
32. The nonsteroidal anti-inflammatory drug Exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome.
Czibere A; Prall WC; Zerbini LF; Grall F; Craigie EC; Ulrich SD; Giagounidis AA; Haas R; Libermann TA; Aivado M
Cell Cycle; 2005 Jun; 4(6):812-7. PubMed ID: 15970671
[TBL] [Abstract][Full Text] [Related]
33. FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome.
Schieber M; Marinaccio C; Bolanos LC; Haffey WD; Greis KD; Starczynowski DT; Crispino JD
Blood Cancer J; 2020 Oct; 10(10):98. PubMed ID: 33024076
[TBL] [Abstract][Full Text] [Related]
34. Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
Liberante FG; Pouryahya T; McMullin MF; Zhang SD; Mills KI
Oncotarget; 2016 Feb; 7(6):6609-19. PubMed ID: 26735888
[TBL] [Abstract][Full Text] [Related]
35. IL-1 receptor antagonist gene polymorphism in patients with secondary acute myeloid leukaemia.
Langabeer SE; Linch DC
Cytokines Cell Mol Ther; 1998 Mar; 4(1):7-9. PubMed ID: 9557211
[TBL] [Abstract][Full Text] [Related]
36. Increased separase activity and occurrence of centrosome aberrations concur with transformation of MDS.
Ruppenthal S; Kleiner H; Nolte F; Fabarius A; Hofmann WK; Nowak D; Seifarth W
PLoS One; 2018; 13(1):e0191734. PubMed ID: 29370237
[TBL] [Abstract][Full Text] [Related]
37. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.
Hallemeier CL; Girgis MD; Blum WG; Brown RA; Khoury HJ; Devine SM; Vij R; Lin HS; DiPersio JF; Adkins DR
Biol Blood Marrow Transplant; 2006 Jul; 12(7):749-57. PubMed ID: 16785064
[TBL] [Abstract][Full Text] [Related]
38. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group.
Arnold R; de Witte T; van Biezen A; Hermans J; Jacobsen N; Runde V; Gratwohl A; Apperley JF
Bone Marrow Transplant; 1998 Jun; 21(12):1213-6. PubMed ID: 9674854
[TBL] [Abstract][Full Text] [Related]
39. Apparent expansion of CD34+ cells during the evolution of myelodysplastic syndromes to acute myeloid leukemia.
Span LF; Dar SE; Shetty V; Mundle SD; Broady-Robinson L; Alvi S; Raymakers RA; de Witte T; Raza A
Leukemia; 1998 Nov; 12(11):1685-95. PubMed ID: 9823942
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes. Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG).
De Witte T; Zwaan F; Hermans J; Vernant J; Kolb H; Vossen J; Lönnqvist B; Beelen D; Ferrant A; Gmür J
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():38-9. PubMed ID: 2697398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
